key: cord-0973642-fnz77n20 authors: Faria, E.; Guedes, A. R.; Oliveira, M. S.; Moreira, M. V. G.; Maia, F. L.; Barboza, A. S.; Leme, M. D.; Letaif, L. S. H.; Miethke-Morais, A.; Bonfa, E.; Segurado, A. C.; Tomazini, F. M.; Santos, A. A.; Figueiredo, P.; Andrade, P. S.; Oliveira, F. M.; Eliodoro, R. H. d. A.; de Jesus, J. G.; Lazari, C. S.; Sabino, E. C.; Costa, S. F.; Pedroso de Lima, A. C.; Levin, A. S. title: Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) - preliminary report date: 2021-04-15 journal: nan DOI: 10.1101/2021.04.12.21255308 sha: d68aed7ed90cea240c31b45a9e954c114ecb2b11 doc_id: 973642 cord_uid: fnz77n20 Background: CoronaVac, a vaccine containing inactivated SARS-CoV-2, demonstrated efficacy of 50.39% 14 days or more after the 2nd dose. The objective of this study is to report the occurrence of symptomatic COVID-19 in a cohort of HCW vaccinated with CoronaVac and to estimate its effectiveness. Methods: CoronaVac was given to HCWs in Hospital das Clinicas on 18-21 January, 2021 (epi week 3) (22,402 HCWs), and on 14-16 February, 2021 (epi week 7) (21,652 HCWs). Weekly cases of symptomatic COVID-19 were evaluated. Using the period from 2020 epi week 24 through 2021 epi week 2 (before vaccination), a Poisson regression was fit to model the HCWs with COVID-19 of the hospital, and the officially reported cases in the city of Sao Paulo. The predicted numbers of cases among HCWs for 2021 epi weeks 3-12 were then compared to the observed numbers of cases (after vaccination). Effectiveness was estimated for weeks 9-12 (2 to 5 weeks after the 2nd dose). 142 samples after vaccination were evaluated for SARS-CoV-2 variants of concern. Results: Since the 1st dose there were 380 HCW diagnosed with COVID-19. On visual analysis, the number of cases of COVID-19 in the city increased sharply in 2021. The number of cases among the HCW did not follow. The estimated effectiveness 2 and 3 weeks after 2nd dose was 50.7% and 51.8%, respectively, and increased over the next 2 weeks. 67/142 samples (47%) were variants of concern, mostly P1 (57). Conclusion: Coronavac is effective in preventing COVID-19. CoronaVac, a vaccine containing inactivated SARS-CoV-2, was well tolerated and induced humoral responses in phase 1 and 2 studies [1] . Interim analysis of phase 3 clinical trial conducted in Brazil evaluating 12,607 participants demonstrated efficacy of 50.39% (95%CI: 35.26 -61.98; p=0.005) when considering 15 days or more after the 2nd dose [2] . Efficacy and effectiveness of vaccines measure the proportion of reduction of a disease among vaccinated persons. The difference is that efficacy is used during a clinical trial, under ideal circumstances and effectiveness is used when a study is performed under everyday conditions, outside of clinical trials [3] . To our knowledge there are no studies on the effectiveness of CoronaVac. The objective of this study is to report the occurrence of symptomatic COVID-19 in a cohort of healthcare workers (HCW) vaccinated with CoronaVac and to estimate its effectiveness. Since the beginning of the COVID-19 pandemic, symptomatic HCWs were directed to specific HCW health services where they were evaluated by a doctor and received a 3-day leave. On day 3 of symptoms they collected oro-nasopharyngeal swabs, tested by RT-PCR for SARS-CoV-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org/10.1101/2021.04.12.21255308 doi: medRxiv preprint 4 2. If negative and asymptomatic they returned to work. If positive, they received paid leave for a total of 14 days. No follow-up testing was done once the HCW was found to be positive. Over 4 days (18- CoronaVac is an inactivated SARS-CoV-2 vaccine developed by Sinovac Life Sciences (Beijing, China). Phase 1/2 studies showed it to be safe and to lead to seroconversion [1] . It was licenced for use in Brazil on 17 January, 2021. Unpublished efficacy has been reported to be 50.39% [2] . CoronaVac vaccination was studied using 2 doses of 600 SU administered 2 to 4 weeks apart. Over the period from 23 February, 2020 (2020 epidemiological week 9) through 28 March, 2021 (2021 epi week 12) we recorded the weekly numbers of HCWs in HC who had symptomatic COVID-19 confirmed by RT-PCR, evaluated by the hospital's HCW health services. Over the same period we evaluated the weekly number of COVID-19 cases and COVID-19 related deaths in the city of São Paulo that is publicly reported [5] ; and the index of immobility [6] . This index is based on the location of cell phones, with data from the 4 mobile phone companies that cover the city. The cell phones are considered to have "slept" in the location registered between 10PM to 2AM. After that, displacements of more than 200m from that point are registered. The index is the proportion of telephones that were not displaced over 24 hours. We presented the average for each epi week. lineages. The samples were also studied using a protocol [9] that is able to distinguish B1.1.7 from P1 and B 1.351 lineages. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org/10.1101/2021.04.12.21255308 doi: medRxiv preprint A Poisson regression model was used to study the relationship between the weekly number of COVID-19 cases among HC HCW, taken as dependent variable, and cases recorded for the general population of São Paulo city. The fit was based on data from the pre-vaccination period, from 2020 epi week 24 to 2021 epi week 2. Residual analyses were then performed, showing two influential points. After removal of such values, a final model was obtained and used to extrapolate the number of cases among HC HCW considering the known values for the population of São Paulo city in the post-vaccination period (2021 epi week 3 to 12). In addition, 95% prediction intervals were computed using the bootstrap resampling method. The observed values of COVID-19 cases among HC HCW were then compared to the predicted ones for the post-vaccination period. Effectiveness estimates and corresponding 95% bootstrap confidence intervals were computed assuming the observed number of HC HCW cases as the vaccinated group and the predicted numbers from the Poisson model as the unvaccinated group. The weekly behaviour of symptomatic COVID-19 among the hospital's HCW, and the publicly available data on the COVID-19 cases in the city of São Paulo can be seen in Figure 1 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The results from the Poisson regression fit considering period from 2020 epi week 24 to 2021 epi week 2 can be seen in Figure 2 . The observed number of cases for HC HCWs for the weeks 3 through 12 post-vaccination period, as well as prediction values and 95% prediction intervals can be seen in Table 1 . The predicted number of cases among HC HCWs can be thought of as what would be observed if this population had not been vaccinated; therefore, the differences between the actual number of cases and the predicted ones may be interpreted as the effect of immunization. None of the prediction intervals includes the observed values, that were always below the interval inferior limit, reinforcing our findings. Among 142 HCW's respiratory samples randomly evaluated, in 67 (47%) variants of concern (VOC) were detected: 57 were variant P1, 5 were B.1.1.7, and 5 were other VOC not identified by our methods. The index of immobility increased at the beginning of the pandemic reaching a peak of 57%. Slowly it decreased and has been relatively stable since November 2020, at about 40% (Supplemental Figure S1 ). (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Despite the studies of efficacy of vaccines against COVID-19, little is known about their effectiveness, or how they perform in real-life conditions. In a large cohort of HCWs who were vaccinated in a mass campaign with CoronaVac, an inactivated SARS-CoV-2 vaccine, we observed an important decrease over time of confirmed symptomatic cases of COVID-19 in relation to what would have been expected considering the epidemiological situation in the same community. The phase 3 trial evaluating CoronaVac included over 12,000 individuals and showed a 50.38% efficacy [2] . The data are still unpublished. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org/10.1101/2021.04.12.21255308 doi: medRxiv preprint 8 Following licencing in Brazil, mass vaccination of HC HCWs was done. This gave us an opportunity to estimate the effectiveness of the vaccine in a large cohort. The preliminary results suggest that it was effective. Although efficacy has been studied and varied among the different vaccines, little has been published on effectiveness of COVID-19 vaccines, that is their effect in real-world conditions. Another interesting finding was the prevalence of variants: almost half of the studied samples. There has been a concern whether vaccination can lead to an increase in infections caused by variants because vaccines may not be efficient against them [14] . However, we believe that this high prevalence, especially of P1, reflects the epidemiological situation in the region. The variant P1 was described as emerging in the Amazon region in Brazil in November 2020 and spread rapidly, becoming the predominant strain in 7 weeks, accounting for 87% of cases [15] . Our study has limitations. In the first place, it is a very preliminary evaluation in which details of affected patients such as severity of disease and deaths were not taken into account. Secondly, the peak of cases among HCWs in HC preceded the peak of cases in the city of São Paulo. We believe that this was due to the lack of diagnosis of mild and moderate cases in the city. In HC, testing was immediately available to all symptomatic HCWs since the beginning of the pandemic. In support of our idea, the peak of deaths in the city was similar to the cases in All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org/10.1101/2021.04.12.21255308 doi: medRxiv preprint 9 our HCWs. It has been discussed that deaths are a more reliable surveillance tool in situations in which testing capacity is limited [17, 18] which was especially true in the beginning of the pandemic in São Paulo. Considering this situation we chose not to include data from 2020 epi weeks 9 through 23 when designing our predictive model. As mentioned earlier, the results for 2021 epi weeks 10-12 should be interpreted with caution, as the numbers of cases in the city of São Paulo in these weeks were outside the range variation observed during parameter estimation of the Poisson regression model. In conclusion, since 2021 epi week 3, when the first dose of CoronaVac was administered to the HCW of the hospital, COVID-19 cases among our HCWs were lower than expected. São Paulo started a second wave of COVID-19 soon after the completion of vaccination in HC, that was not reflected among our HCWs. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org/10.1101/2021.04.12.21255308 doi: medRxiv preprint Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Autorização de Uso Emergencial de Vacinas contra a COVID-19 A Primer on Effectiveness and Efficacy Trials Dados abertos. Registro de casos e óbitos por município e data de notificação no Estado de São Paulo Adesão ao isolamento social em SP. Available at: synthesized across a multi-state health system Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS 13-Aran D. Estimating real-world COVID-19 vaccine effectiveness in Israel Science in 5. Episode #31-Vaccines, variants & doses Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus Covid-19 deaths in Africa: prospective systematic postmortem surveillance study Tracking excess deaths associated with the COVID-19 epidemic as an epidemiological surveillance strategy-preliminary results of the evaluation of six Brazilian capitals All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted April 15, 2021. ; https://doi.org/10.1101/2021.04.12.21255308 doi: medRxiv preprint